3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 1
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Sarcoma
34
Gynecologic
7
Dermatologic
7
CNS
7
Thoracic
6
Genitourinary
6
Gastrointestinal
6
Other solid neoplasm
3
Lymphoid
3
Head & Neck
2
Breast
2
Plasma cell
1
NET
1
Endocrine
1
Conditions
Lymphoma
539
Precursor Cell Lymphoblastic Leukemia-Lymphoma
499
Lymphoma, Non-Hodgkin
435
Lymphoma, Follicular
403
Leukemia, Lymphocytic, Chronic, B-Cell
388
Lymphoma, Large B-Cell, Diffuse
385
Lymphoma, B-Cell
246
Lymphoma, Mantle-Cell
222
Hodgkin Disease
207
Recurrence
204
Leukemia, Myeloid, Acute
197
Leukemia
191
Multiple Myeloma
184
Burkitt Lymphoma
181
Lymphoma, B-Cell, Marginal Zone
170
Neoplasms
151
Myelodysplastic Syndromes
132
Hematologic Neoplasms
115
Waldenstrom Macroglobulinemia
103
Lymphoma, T-Cell, Peripheral
85
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
81
Lymphoma, T-Cell
81
Lymphoma, T-Cell, Cutaneous
66
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
62
Mycosis Fungoides
57
Leukemia, Biphenotypic, Acute
54
Breast Neoplasms
54
Myeloproliferative Disorders
50
Leukemia, B-Cell
50
Lymphoproliferative Disorders
47
Interventions
tazemetostat
1
CLR1404
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Sarcoma, Synovial
×
Lymphoid
×
1 year
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled
NCT02875548
2025-11-04
TRuST
Ipsen
Phase 1/2
Completed
58 enrolled
NCT07066982
2025-07-15
BAH2573-103
Essen Biotech
Phase 1/2
Recruiting
60 enrolled